Bispecific antibodies (BsAb), multi-specific antibodies (MsAb) and Fc-fusion proteins offer several advantages over monoclonal antibodies (mAbs) in drug development, primarily through enhanced therapeutic efficacy, broader target engagement, and improved pharmacokinetics. However, complex molecule development presents unique challenges in Chemistry, Manufacturing, and Controls (CMC) due to their structural complexity, heterogeneity, and functional diversity.

In this whitepaper, Angie Yu, Director of Technical Innovation at Altruist Biologics, explores how a mature and comprehensive platform with advanced cell line development, process optimization, analytical characterization, and formulation strategies can address these challenges while ensuring robust process scalability, quality control strategies, and regulatory compliance from early-stage development to commercial production.

Read on to see how Altruist Biologics’ multifaceted approach integrating advanced technologies and strategic frameworks can help create a seamless path forward.